Spark Therapeutics shares slide after a setback on its hemophilia gene therapy study
Shares of Spark Therapeutics $ONCE, the most advanced gene therapy company in a growing field, were badly dented this morning after the Pfizer $PFE partner …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
